Multicenter randomized phase III trial of Epirubicin plus Paclitaxel vs Epirubicin followed by Paclitaxel in metastatic breast cancer patients: focus on cardiac safety

The aim of the study was to evaluate cardiac safety of two different schedules of Epirubicin and Paclitaxel in advanced breast cancer patients enrolled into a multicenter randomized phase III trial. Patients received Epirubicin 90 mg m(−2) plus Paclitaxel 200 mg m(−2) (3-h infusion) on day 1 every 3...

Descripción completa

Detalles Bibliográficos
Autores principales: Baldini, E, Prochilo, T, Salvadori, B, Bolognesi, A, Aldrighetti, D, Venturini, M, Rosso, R, Carnino, F, Gallo, L, Giannessi, P, Conte, P F, Orlandini, C, Bruzzi, P
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364750/
https://www.ncbi.nlm.nih.gov/pubmed/15173858
http://dx.doi.org/10.1038/sj.bjc.6601883

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364750/
https://www.ncbi.nlm.nih.gov/pubmed/15173858
http://dx.doi.org/10.1038/sj.bjc.6601883

Ejemplares similares